Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-HIE: Prophylactic Dobutamine in Neonatal HIE
NCT07406477Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dobutamine in hypoxic-ischemic encephalopathy (HIE), sponsored by University of Alberta. Started Oct 2026; status: recruiting.
02
Drugs
dobutamine
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT07406477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406477.